Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Karyopharm Therapeut (KPTI)

Karyopharm Therapeut (KPTI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Karyopharm Presents XPOVIO(R) (Selinexor) and Eltanexor Data at the American Society of Hematology 2019 Annual Meeting

-- Once-Weekly Oral Selinexor in Combination with Weekly Kyprolis(R) and Low Dose Dexamethasone Demonstrates 71% Overall Response Rate, Including a Complete Response Rate of 21%, in Patients with Heavily...

KPTI : 16.75 (-1.50%)
Karyopharm Reports New and Updated XPOVIO(R) (Selinexor) Data in Relapsed or Refractory Multiple Myeloma at the American Society of Hematology 2019 Annual Meeting

-- All Oral Regimen of Once Weekly Selinexor in Combination with Daily Pomalyst and Low Dose Dexamethasone Demonstrates 56% Overall Response Rate in Pomalyst-Naive and Revlimid-Relapsed or -Refractory...

KPTI : 16.75 (-1.50%)
Shares of Karyopharm Thera Rank the Highest in Terms of Relative Performance in the Biotechnology Industry (KPTI , EXEL , CLVS , VRTX , ALXN )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

CLVS : 12.86 (-4.24%)
EXEL : 17.82 (+0.96%)
KPTI : 16.75 (-1.50%)
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase...

KPTI : 16.75 (-1.50%)
Are You Looking for a Top Momentum Pick? Why Karyopharm Therapeutics (KPTI) is a Great Choice

Does Karyopharm Therapeutics (KPTI) have what it takes to be a top stock pick for momentum investors? Let's find out.

KPTI : 16.75 (-1.50%)
Best Relative Performance in the Biotechnology Industry Detected in Shares of Cytomx Therapeut (CTMX , SPPI , KPTI , CYTK , ALNY )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

CTMX : 7.16 (+0.56%)
KPTI : 16.75 (-1.50%)
SPPI : 8.36 (-3.91%)
After Yesterday's Rally of 4.42% Shares Could Potentially Pullback

Karyopharm Thera (NASDAQ:KPTI) traded in a range yesterday that spanned from a low of $15.50 to a high of $16.32. Yesterday, the shares gained 4.4%, which took the trading range above the 3-day high...

KPTI : 16.75 (-1.50%)
Karyopharm Thera Set to Possibly Pullback After Yesterday's Rally of 48.01%

Karyopharm Thera (NASDAQ:KPTI) traded in a range yesterday that spanned from a low of $14.60 to a high of $15.07. Yesterday, the shares gained 48.0%, which took the trading range above the 3-day high...

KPTI : 16.75 (-1.50%)
Watch for Karyopharm Thera to Potentially Pullback After Gaining 42.78% Yesterday

Karyopharm Thera (NASDAQ:KPTI) traded in a range yesterday that spanned from a low of $14.15 to a high of $14.69. Yesterday, the shares gained 42.8%, which took the trading range above the 3-day high...

KPTI : 16.75 (-1.50%)
Karyopharm Announces XPOVIO(R) (Selinexor) Clinical Data to be Presented at the American Society of Hematology 2019 Annual Meeting

-- Updated Results from the Pomalyst(R) and Kyprolis(R) Arms of the Phase 1b/2 STOMP Study Evaluating Selinexor in Combination with Other Approved Myeloma Therapies in Relapsed or Refractory Multiple Myeloma...

KPTI : 16.75 (-1.50%)
Karyopharm (KPTI) Catches Eye: Stock Jumps 6.4%

Karyopharm (KPTI) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

FGEN : 46.69 (-1.99%)
KPTI : 16.75 (-1.50%)
Karyopharm Thera has the Best Relative Performance in the Biotechnology Industry (KPTI , IRWD , SRPT , TGTX , DVAX )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

IRWD : 12.79 (+1.35%)
KPTI : 16.75 (-1.50%)
SRPT : 132.05 (+31.43%)
Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 20.24% and 718.23%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?...

KPTI : 16.75 (-1.50%)
Karyopharm Therapeutics: 3Q Earnings Snapshot

NEWTON, Mass. (AP) _ Karyopharm Therapeutics Inc. (KPTI) on Monday reported a loss of $41.4 million in its third quarter.

KPTI : 16.75 (-1.50%)
Karyopharm Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress

â?' XPOVIO Phase 2b STORM Study Results Published in The New England Journal of Medicine â?'

KPTI : 16.75 (-1.50%)
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase...

KPTI : 16.75 (-1.50%)
Karyopharm to Report Third Quarter 2019 Financial Results on November 4, 2019

Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that it will report third quarter 2019 financial results on Monday, November 4, 2019. Karyopharm's...

KPTI : 16.75 (-1.50%)
Shareholder Alert: Robbins Arroyo LLP Reminds Investors Karyopharm Therapeutics Inc. (KPTI) Sued for Misleading Shareholders

Shareholder rights law firm Robbins Arroyo LLP reminds investors that a purchaser of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) filed a class action complaint for alleged violations of the Securities...

KPTI : 16.75 (-1.50%)
Amag Pharmaceuti is Among the Companies in the Biotechnology Industry with the Best Relative Performance (AMAG , CHRS , KPTI , EXAS , EXEL )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

AMAG : 11.15 (-1.59%)
CHRS : 18.52 (+1.48%)
KPTI : 16.75 (-1.50%)
Shares of Pfenex Inc Rank the Highest in Terms of Relative Performance in the Biotechnology Industry (PFNX, VCYT , KPTI , GBT , REGN )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

KPTI : 16.75 (-1.50%)
VCYT : 28.51 (-0.42%)
PFNX : 11.73 (+5.20%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI +0.68 , AIZ -0.29 , SBAC +7.43 , SO +0.05 , WELL -0.46
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar